Download This PaperAccess to Global Disease Innovation
7 Pages Posted: 16 Nov 2006
Date Written: November 15, 2006
Abstract
The pharmaceutical IP system works well in high-income countries able to afford government subsidies and social insurance. It does not work for the poor in low and middle-income countries. For global diseases (Types I and II), innovation is assured by high-income country markets alone, permitting an accommodation for the poor in low and medium-income countries such as a patent buyout or other access programs which support equitable access without damaging optimal innovation incentives.
Keywords: intellectual property, IP, access, innovation, essential medicines, patent, pharmaceutical
Suggested Citation: Suggested Citation
Outterson, Kevin, Access to Global Disease Innovation (November 15, 2006). Available at SSRN: https://ssrn.com/abstract=884241 or http://dx.doi.org/10.2139/ssrn.884241
Do you have negative results from your research you’d like to share?
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.